Financial Relationships between Organizations That Produce Clinical Practice Guidelines and the Biomedical Industry: A Cross-Sectional Study

1. Tricoci P, Allen JM, Kramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009;301:831–841. doi: 10.1001/jama.2009.205 19244190

2. Norris SL, Holmer HK, Ogden LA, Selph SS, Fu R. Conflict of interest disclosures for clinical practice guidelines in the national guideline clearinghouse. PLoS ONE. 2012;7:e47343. doi: 10.1371/journal.pone.0047343 23144816

3. Lo B, Field MJ, editors. Conflict of interest in medical research, education, and practice. Institute of Medicine. Washington (District of Columbia): National Academies Press; 2009.

4. Norris SL, Holmer HK, Ogden LA, Burda BU. Conflict of interest in clinical practice guideline development: a systematic review. PLoS ONE. 2011;6:e25153. doi: 10.1371/journal.pone.0025153 22039406

5. Choudhry NK, Stelfox HT, Detsky AS. Relationships between authors of clinical practice guidelines and the pharmaceutical industry. JAMA. 2002;287:612–617. 11829700

6. Steinbrook R. Guidance for guidelines. N Engl J Med. 2007;356:331–333. 17251529

7. Bindslev JB, Schroll J, Gotzsche PC, Lundh A. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. BMC Med Ethics. 2013;14:19. doi: 10.1186/1472-6939-14-19 23642105

8. Boyd EA, Akl EA, Baumann M, Curtis JR, Field MJ, Jaeschke R, et al. Guideline funding and conflicts of interest: article 4 in integrating and coordinating efforts in COPD guideline development. An official ATS/ERS workshop report. Proc Am Thorac Soc. 2012;9:234–242. doi: 10.1513/pats.201208-057ST 23256165

9. Taylor R, Giles J. Cash interests taint drug advice. Nature. 2005;437:1070–1071. 16237402

10. Emanuel EJ, Thompson DF. The concept of conflicts of interest. In: Emanuel EJ, editor. The Oxford textbook of clinical research ethics. Oxford: Oxford University Press; 2008. pp. 758–766.

11. Thompson DF. Understanding financial conflicts of interest. N Engl J Med. 1993;329:573–576. 8336759

12. Field MJ, Lohr KN, editors. Clinical practice guidelines: directions for a new program. Institute of Medicine. Washington (District of Columbia): National Academies Press; 1990.

13. Agency for Healthcare Research and Quality. National Guideline Clearinghouse: inclusion criteria. 2014 Dec 10 [cited 19 Jan 2016]. Available: http://www.guideline.gov/about/inclusion-criteria.aspx.

14. Agency for Healthcare Research and Quality. National Guideline Clearinghouse. 2013 [cited 9 Jun2013]. Available: http://www.guideline.gov.

15. Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66:719–725. doi: 10.1016/j.jclinepi.2012.03.013 23312392

16. Jacobs AK, Anderson JL, Halperin JL, ACC/AHA Task Force Members. The evolution and future of ACC/AHA clinical practice guidelines: a 30-year journey: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;130:1208–1217. doi: 10.1161/CIR.0000000000000090 25092464

17. Guyatt GH, Oxman AD, Kunz R, Falck-Ytter Y, Vist GE, Liberati A, et al. Going from evidence to recommendations. BMJ. 2008;336:1049–1051. doi: 10.1136/bmj.39493.646875.AE 18467413

18. US Department of Health and Human Services. Approved drug products with therapeutic equivalence evaluations. 33rd ed. Washington (District of Columbia): US Department of Health and Human Services; 2013. 1346 p.

19. Council of Medical Specialty Societies. Code for interactions with companies. 2015 Apr [cited 5 May 2016]. Available: http://cmss.org/wp-content/uploads/2016/02/CMSS-Code-for-Interactions-with-Companies-Approved-Revised-Version-4.13.15-with-Annotations.pdf.

20. Baumann MH, Lewis SZ, Gutterman D. ACCP evidence-based guideline development: a successful and transparent approach addressing conflict of interest, funding, and patient-centered recommendations. Chest. 2007;132:1015–1024. 17540835

21. Burns KE, Duffett M, Kho ME, Meade MO, Adhikari NK, Sinuff T, et al. A guide for the design and conduct of self-administered surveys of clinicians. CMAJ. 2008;179:245–252. doi: 10.1503/cmaj.080372 18663204

22. Dillman DA. Mail and telephone surveys: the total design method. New York: Wiley-Interscience; 1978.

23. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174. 843571

24. Zeger SL, Liang KY. Longitudinal data analysis for discrete and continous outcomes. Biometrics. 1986;42:121–130. 3719049

25. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000;283:373–380. 10647801

26. Orlowski JP, Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. There’s no such thing as a free lunch. Chest. 1992;102:270–273. 1623766

27. Whittington CJ, Kendall T, Fonagy P, Cottrell D, Cotgrove A, Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet. 2004;363:1341–1345. 15110490

28. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsorship and research outcome. Cochrane Database Syst Rev. 2012;12:MR000033. doi: 10.1002/14651858.MR000033.pub2 23235689

29. Licurse A, Barber E, Joffe S, Gross C. The impact of disclosing financial ties in research and clinical care: a systematic review. Arch Int Med. 2010;170:675–682.

30. Drazen JM, Van Der Weyden MB, Sahni P, Rosenberg J, Marusic A, Laine C, et al. Uniform format for disclosure of competing interests in ICMJE journals. Lancet. 2009;374:1395–1396. doi: 10.1016/S0140-6736(09)61796-7 19836071

31. International Committee of Medical Journal Editors. Author responsibilities—conflicts of interest. 2015 [cited 10 Mar 2015]. Available: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/author-responsibilities—conflicts-of-interest.html

32. Association of American Medical Colleges. In the interest of the patients: recommendations for physician financial relationships and clinical decision making. 2010 Jun [cited 10 Mar 2015]. Available: https://members.aamc.org/eweb/upload/In the Interest of Patients.pdf.

33. Kuehn BM. Payments to physicians, medical schools to be illuminated under new reform law. JAMA. 2010;303:2237–2238. doi: 10.1001/jama.2010.724 20530769

34. GlaxoSmithKline. Corporate responsibility report 2013. 2013 [cited 10 Mar 2015]. Available: http://www.gsk.com/media/325170/cr-report-2013.pdf.

35. Ransohoff DF, Pignone M, Sox HC. How to decide whether a clinical practice guideline is trustworthy. JAMA. 2013;309:139–140. doi: 10.1001/jama.2012.156703 23299601

36. Loewenstein G, Sah S, Cain DM. The unintended consequences of conflict of interest disclosure. JAMA. 2012;307:669–670. doi: 10.1001/jama.2012.154 22337676

37. Krimsky S. Combating the funding effect in science: what’s beyond transparency? Stanford Law Pol Rev. 2010;21:101–123.

38. Neuman J, Korenstein D, Ross JS, Keyhani S. Prevalence of financial conflicts of interest among panel members producing clinical practice guidelines in Canada and United States: cross sectional study. BMJ. 2011;343:d5621. doi: 10.1136/bmj.d5621 21990257

39. Roseman M, Turner EH, Lexchin J, Coyne JC, Bero LA, Thombs BD. Reporting of conflicts of interest from drug trials in Cochrane reviews: cross sectional study. BMJ. 2012;345:e5155. doi: 10.1136/bmj.e5155 22906823